Assyro AI

FDA Orange Book · active-ingredient family

Trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)

Trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) is approved as 3 brand and 8 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:NEOTRIZINE · NDA 006317

3

Brand (NDA)

8

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · suspension, tablet

ProductApplicantApplicationTEApproved
NEOTRIZINE×2LILLYNDA 006317Approved Prior to Jan 1, 1982
TERFONYL×2BRISTOL MYERS SQUIBBNDA 006904Approved Prior to Jan 1, 1982
TRIPLE SULFAS×2LEDERLENDA 006920Approved Prior to Jan 1, 1982

Generic (ANDA) products (8)

ProductApplicantApplicationTEApproved
LANTRISULLANNETTANDA 080123Approved Prior to Jan 1, 1982
SULFALOIDFOREST PHARMSANDA 080100Approved Prior to Jan 1, 1982
SULFOSE×2WYETH AYERSTANDA 080013Approved Prior to Jan 1, 1982
TRIPLE SULFAALPHARMA US PHARMSANDA 080280Approved Prior to Jan 1, 1982
SULFA-TRIPLE #2IMPAX LABSANDA 080079Approved Prior to Jan 1, 1982
SULFALOIDFOREST PHARMSANDA 080099Approved Prior to Jan 1, 1982
TRIPLE SULFAPUREPAC PHARMANDA 080086Approved Prior to Jan 1, 1982
TRIPLE SULFOIDPAL PAKANDA 080094Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.